1. Drugs in focus : budesonide and its role in paediatric gastrointestinal disordersSohail Aziz, Maria Giovanna Puoti, Amit Assa, Zrinjka Mišak, Emmanuel Mas, Osvaldo Borrelli, Jernej Dolinšek, Javier Martin-de-Carpi, Isabelle Scheers, Christos Tzivinikos, Matjaž Homan, Caterina Strisciuglio, 2026, pregledni znanstveni članek Ključne besede: adrenal suppression, corticosteroids
Objavljeno v DiRROS: 22.04.2026; Ogledov: 132; Prenosov: 129
 Celotno besedilo (1,44 MB)
Gradivo ima več datotek! Več... |
2. Approach to anaemia in gastrointestinal disease: a position paper by the ESPGHAN Gastroenterology CommitteeIlse Broekaert, Amit Assa, Osvaldo Borrelli, Marco Deganello Saccomani, Matjaž Homan, Javier Martin-de-Carpi, Emmanuel Mas, Erasmo Miele, Zrinjka Mišak, Sara Sila, Mike Thomson, Christos Tzivinikos, Jernej Dolinšek, 2025, pregledni znanstveni članek Objavljeno v DiRROS: 22.04.2026; Ogledov: 122; Prenosov: 132
Celotno besedilo (2,69 MB)
Gradivo ima več datotek! Več... |
3. Helicobacter pylori infection in children Versus adults, differences in management guidelines: risks and benefits of treatment in childhoodMatjaž Homan, Zrinjka Mišak, Francis Megraud, Michal Kori, 2025, izvirni znanstveni članek Povzetek: Helicobacter pylori infection in children and adults differs in several aspects such as the natural history, prevalence, the clinical presentations and complications, antibiotic resistance rates, treatment options, and the success rates of treatment. Due to all the abovementioned differences, management guidelines and recommendations are different between children and adults. In parallel to the steady decrease in the rate of H. pylori infection in the Western world in recent years, both in children and adults, antibiotic resistance rates have risen to alarming rates. The risk and benefits of eradication treatment, especially in children, must be considered when deciding “to treat or not.” The risks include the negative effects of antibiotics, treatment failure, and reinfection as well as the possibility of losing the “protective effect” of H. pylori on atopy, allergy, and possibly on other gastrointestinal diseases. On the other hand, there are also many benefits of eradication therapy such as prevention of gastric complication and associated non-gastric complications as well as reduction of parental anxiety of nontreatment. This review summarizes the differences related to H. pylori in children versus adults and the risks and benefits of treatment in children.
Ključne besede: children, adults, treatment, Helicobacter pylori
Objavljeno v DiRROS: 14.01.2026; Ogledov: 442; Prenosov: 297
Celotno besedilo (347,94 KB)
Gradivo ima več datotek! Več... |
4. Intestinal involvement in graft versus host disease in children : an overview by the ESPGHAN Gastroenterology CommitteeMarina Vincent, Amit Assa, Osvaldo Borrelli, Matjaž Homan, Javier Martin-de-Carpi, Zrinjka Mišak, Maria Giovanna Puoti, Isabelle Scheers, Sara Sila, Caterina Strisciuglio, Christos Tzivinikos, Jernej Dolinšek, Emmanuel Mas, 2025, pregledni znanstveni članek Povzetek: Graft versus host disease (GVHD) is a complication that frequently occurs afterhaematopoietic stem cell transplantation and concerns many children in paediatrichaematology‐oncology and bone marrow transplantation departments. It can affectvarious organs, with the skin, gastrointestinal tract and liver being the most com-monly involved. To confirm intestinal GVHD and to rule out differential diagnosesendoscopy is frequently needed. Currently, there are no specific consensus rec-ommendations concerning the best method for endoscopic exploration and medicalmanagement of this disease in children, with limited studies available, including alow number of patients. Sigmoidoscopy could be initially proposed under sedation. Ifsigmoidoscopy is normal or if a general anaesthesia is required, colonoscopy andupper endoscopy should be planned, avoiding duodenal biopsy because of the riskof duodenal haematoma. Regarding therapeutic options, corticosteroids are thefirst‐line treatment for GVHD. Ruxolitinib, a Janus kinase inhibitor, is indicated forchildren aged 12 years and older with acute or chronic GVHD who have aninadequate response to corticosteroids or other systemic therapies. Nutritionalsupport has a key role in the management of intestinal GVHD and should beconsidered to guarantee the best possible evolution of intestinal GVHD.
Ključne besede: GVHD, children, complication, endoscopy, haematopoietic stem cell transplantation, intestine
Objavljeno v DiRROS: 14.11.2025; Ogledov: 355; Prenosov: 235
Celotno besedilo (770,51 KB)
Gradivo ima več datotek! Več... |
